Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


14.06.2021

1 Acta Radiol
1 AJR Am J Roentgenol
1 Am J Clin Oncol
1 Am J Surg Pathol
2 Anticancer Res
2 BJU Int
2 BMC Cancer
2 Br J Radiol
5 Cancer
2 Cancer Lett
4 Clin Cancer Res
1 Eur J Radiol
5 Eur Urol
3 Int J Radiat Oncol Biol Phys
1 Invest Radiol
5 J Clin Oncol
2 J Magn Reson Imaging
2 J Nucl Med
1 Lancet Oncol
1 Oncogene
1 PLoS Med
2 PLoS One
5 Prostate
1 Semin Radiat Oncol
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Radiol

  1. LINHARES MOREIRA AS, De Visschere P, Van Praet C, Villeirs G, et al
    How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.
    Acta Radiol. 2021;62:839-847.
    PubMed         Abstract available


    AJR Am J Roentgenol

  2. SCIALPI M, Scialpi P, Blasi AD
    Prostate Biparametric MRI: PI-RADS Committee Position and Perspectives.
    AJR Am J Roentgenol. 2021 Apr 21:W1. doi: 10.2214/AJR.21.25443.
    PubMed        


    Am J Clin Oncol

  3. MERRICK GS, Galbreath R, Fiano R, Scholl W, et al
    The Impact of Body Mass Index on Freedom From Therapeutic Intervention and Quality of Life in Active Surveillance Prostate Cancer Patients.
    Am J Clin Oncol. 2021 Jun 7. pii: 00000421-900000000-98553.
    PubMed         Abstract available


    Am J Surg Pathol

  4. DENG FM, Isaila B, Jones D, Ren Q, et al
    Optimal Method for Reporting Prostate Cancer Grade in MRI-targeted Biopsies.
    Am J Surg Pathol. 2021 Jun 10. pii: 00000478-900000000-97181.
    PubMed         Abstract available


    Anticancer Res

  5. PEPE P, Pepe L, Pennisi M, Fraggetta F, et al
    Prostate Cancer Diagnosis and Management During One Year of the COVID-19 Pandemic.
    Anticancer Res. 2021;41:3127-3130.
    PubMed         Abstract available

  6. GARRIDO MM, Ribeiro RM, Kruger K, Pinheiro LC, et al
    Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?
    Anticancer Res. 2021;41:3067-3073.
    PubMed         Abstract available


    BJU Int

  7. ALBERTSEN P
    Prostate cancer: the interplay between genetics and the environment.
    BJU Int. 2021;127:615-616.
    PubMed        

  8. YAXLEY J
    Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
    BJU Int. 2021;127:747.
    PubMed        


    BMC Cancer

  9. CHONG W, Zhang Z, Luo R, Gu J, et al
    Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    BMC Cancer. 2021;21:655.
    PubMed         Abstract available

  10. ELLIS SD, Hwang S, Morrow E, Kimminau KS, et al
    Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.
    BMC Cancer. 2021;21:649.
    PubMed         Abstract available


    Br J Radiol

  11. QUINTERO P, Cheng Y, Benoit D, Moore C, et al
    Effect of treatment planning system parameters on beam modulation complexity for treatment plans with single-layer multi-leaf collimator and dual-layer stacked multi-leaf collimator.
    Br J Radiol. 2021;94:20201011.
    PubMed         Abstract available

  12. KUMASAKA S, Motegi S, Kumasaka Y, Nishikata T, et al
    Whole-body magnetic resonance imaging (WB-MRI) with diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in prostate cancer: Prevalence and clinical significance of incidental findings.
    Br J Radiol. 2021 Jun 11:20210459. doi: 10.1259/bjr.20210459.
    PubMed         Abstract available


    Cancer

  13. PARIKH RB, Gallo JJ, Wong YN, Robinson KW, et al
    Long-term depression incidence and associated mortality among African American and White prostate cancer survivors.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33656.
    PubMed         Abstract available

  14. HOWARD DH, Quek RGW, Fox KM, Arondekar B, et al
    The value of new drugs for advanced prostate cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33662.
    PubMed         Abstract available

  15. HUDNALL MT, Desai AS, Tsai KP, Weiner AB, et al
    It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33621.
    PubMed         Abstract available

  16. KIM DW, Chen MH, Wu J, Huland H, et al
    Prostate-specific antigen levels of 4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
    Cancer. 2021;127:2222-2228.
    PubMed         Abstract available

  17. MCMAHON GC, Leapman MS
    A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk.
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33619.
    PubMed        


    Cancer Lett

  18. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    PubMed         Abstract available

  19. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    PubMed         Abstract available


    Clin Cancer Res

  20. SMITH MR, Thomas S, Gormley M, Chowdhury S, et al
    Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0358.
    PubMed         Abstract available

  21. MUNN LL, Stylianopoulos T, Jain NK, Hardin CC, et al
    Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
    Clin Cancer Res. 2021;27:2706-2711.
    PubMed         Abstract available

  22. ANNALA M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, et al
    Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1625.
    PubMed         Abstract available

  23. FONG L, Morris MJ, Sartor O, Higano CS, et al
    A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0063.
    PubMed         Abstract available


    Eur J Radiol

  24. ARSLAN A, Alis D, Tuna MB, Saglican Y, et al
    The visibility of prostate cancer concerning underlying histopathological variances: A single-center multiparametric magnetic resonance imaging study.
    Eur J Radiol. 2021;141:109791.
    PubMed         Abstract available


    Eur Urol

  25. SUMANASURIYA S, Seed G, Parr H, Christova R, et al
    Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    Eur Urol. 2021 Jun 5. pii: S0302-2838(21)01799.
    PubMed         Abstract available

  26. CHOW AK, Vourganti S, Konety BR
    Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Eur Urol. 2021 Jun 3. pii: S0302-2838(21)01796.
    PubMed        

  27. SATISH P, Simpson B, Freeman A, Giganti F, et al
    Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk.
    Eur Urol. 2021 May 28. pii: S0302-2838(21)00355.
    PubMed        

  28. PADHANI AR, Rouviere O, Schoots IG
    Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00393.
    PubMed        

  29. LIAUW SL
    High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00392.
    PubMed        


    Int J Radiat Oncol Biol Phys

  30. KISHAN AU, Collins SP
    Quality of Life After Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;110:727-730.
    PubMed        

  31. MOHAMAD O, Feng F
    Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
    Int J Radiat Oncol Biol Phys. 2021;110:634-635.
    PubMed        

  32. BELKACEMI Y, Coraggio G, Loganadane G
    Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
    Int J Radiat Oncol Biol Phys. 2021;110:631-632.
    PubMed        


    Invest Radiol

  33. KHALIGHINEJAD P, Parrott D, Jordan VC, Chirayil S, et al
    Magnetic Resonance Imaging Detection of Glucose-Stimulated Zinc Secretion in the Enlarged Dog Prostate as a Potential Method for Differentiating Prostate Cancer From Benign Prostatic Hyperplasia.
    Invest Radiol. 2021;56:450-457.
    PubMed         Abstract available


    J Clin Oncol

  34. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2021 Jun 4:JCO2003714. doi: 10.1200/JCO.20.03714.
    PubMed         Abstract available

  35. VOGELIUS IR, Bentzen SM
    Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?
    J Clin Oncol. 2021 Jun 4:JCO2100586. doi: 10.1200/JCO.21.00586.
    PubMed        

  36. YANG DD, Nguyen PL, D'Amico AV
    Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.
    J Clin Oncol. 2021 Jun 4:JCO2100621. doi: 10.1200/JCO.21.00621.
    PubMed        

  37. BRENNEMAN RJ, Baumann BC, Gay HA, Michalski JM, et al
    Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Jun 4:JCO2100634. doi: 10.1200/JCO.21.00634.
    PubMed        

  38. DESS RT, Jackson WC, Spratt DE
    End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?
    J Clin Oncol. 2021 Jun 4:JCO2100376. doi: 10.1200/JCO.21.00376.
    PubMed        


    J Magn Reson Imaging

  39. SATO T, Isoda H, Fujimoto K, Furuta A, et al
    Evaluation of Weighted Diffusion Subtraction for Detection of Clinically Significant Prostate Cancer.
    J Magn Reson Imaging. 2021 Jun 4. doi: 10.1002/jmri.27771.
    PubMed         Abstract available

  40. SHIRADKAR R
    Editorial for "Multiparametric MRI-Based Peritumoral Radiomics for Preoperative Prediction of the Presence of Extracapsular Extension With Prostate Cancer".
    J Magn Reson Imaging. 2021 May 28. doi: 10.1002/jmri.27747.
    PubMed        


    J Nucl Med

  41. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    PubMed         Abstract available

  42. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    PubMed         Abstract available


    Lancet Oncol

  43. SUNDAR S, Symonds P
    Prostate ultra-radical radiotherapy: reinventing the wheel.
    Lancet Oncol. 2021;22:e223.
    PubMed        


    Oncogene

  44. LIAO Y, Liu Y, Shao Z, Xia X, et al
    A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01851.
    PubMed         Abstract available


    PLoS Med

  45. XU X, Kharazmi E, Tian Y, Mukama T, et al
    Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study.
    PLoS Med. 2021;18:e1003616.
    PubMed         Abstract available


    PLoS One


  46. Retraction: Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer.
    PLoS One. 2021;16:e0253350.
    PubMed        

  47. LOUGHNEY L, McGowan R, O'Malley K, McCaffrey N, et al
    Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study.
    PLoS One. 2021;16:e0253018.
    PubMed         Abstract available


    Prostate

  48. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    PubMed         Abstract available

  49. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    PubMed         Abstract available

  50. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    PubMed         Abstract available

  51. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    PubMed         Abstract available

  52. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    PubMed         Abstract available


    Semin Radiat Oncol

  53. DEEK MP, Phillips RM, Tran PT
    Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.
    Semin Radiat Oncol. 2021;31:242-249.
    PubMed         Abstract available


    Urology

  54. HESTERBERG AB, Gordetsky JB, Hurley PJ
    Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
    Urology. 2021 May 28. pii: S0090-4295(21)00442.
    PubMed         Abstract available

  55. CHAO B, Lepor H
    5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer.
    Urology. 2021 Jun 3. pii: S0090-4295(21)00460.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: